ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 2,150,000 shares, a decrease of 8.5% from the December 15th total of 2,350,000 shares. Based on an average daily trading volume, of 252,300 shares, the days-to-cover ratio is currently 8.5 days.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 in the last three months. 12.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth about $544,000. Assenagon Asset Management S.A. increased its position in shares of ANI Pharmaceuticals by 67.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company’s stock valued at $17,226,000 after purchasing an additional 125,438 shares during the period. JPMorgan Chase & Co. raised its stake in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Principal Financial Group Inc. lifted its position in ANI Pharmaceuticals by 6.9% in the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after purchasing an additional 5,829 shares during the period. Finally, Franklin Resources Inc. boosted its stake in ANI Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock worth $705,000 after buying an additional 691 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Up 1.7 %

NASDAQ:ANIP traded up $0.96 during mid-day trading on Friday, reaching $58.46. The stock had a trading volume of 302,520 shares, compared to its average volume of 215,598. The business’s 50 day moving average is $56.36 and its 200 day moving average is $58.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of research analyst reports. Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.